Patient No. 1 and the cancer trial here that just might change everything
Cincinnati Enquirer (Aug. 8, 2018) If you saw Bob Rulli on the street, you’d never guess he had cancer. He's the first person to receive a first-of-its-kind drug made in Cincinnati. (Photo: Kareem Elgazzar/The Enquirer) [...]
Bexion Pharmaceuticals, Inc. Announces Grant from CancerFree KIDS
CancerFree KIDS Awards Nationwide Children’s Hospital Monies to Initiate Pediatric Trial FOR IMMEDIATE RELEASE Covington, KY, June 19, 2018 - Sometimes things come full circle. Fourteen years ago , CancerFree KIDS awarded its very first [...]
Bexion Pharmaceuticals, Inc. Announces Data at 2018 ASCO Annual Meeting from Ongoing Phase I BXQ-350 Clinical Trial
FOR IMMEDIATE RELEASE Covington, KY ~ June 12, 2018 - Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, discussed data from 17 patients enrolled in the Phase Ia portion of [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
Clinical Trials
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857